Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/25/2026

1. AKAM
2. COST
3. SPY
4. ZS
5. NVDA
6. META
7. DRI
8. ULS
9. PRME
10. CRL

Go back to Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
(NASDAQ: PHVS) Delayed: 32.32 -0.67 (2.03%)
Previous Close $32.99    52 Week High $ 
Open $33.08    52 Week Low $ 
Day High $33.62    P/E N/A 
Day Low $32.14    EPS $ 
Volume 115,566